EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization

Shuting Xu, Jia Li, Kaiqi Long, Xiaoling Liang, Weiping Wang iD

Advanced Science · 2024

DOI: 10.1002/advs.202404218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Shuting Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, 999077, China. Hauptthemen laut MEDLINE: Choroidal Neovascularization, Angiogenesis Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Choroidal neovascularization (CNV) underlies the crux of many angiogenic eye disorders. Although medications that target vascular endothelial growth factor (VEGF) are approved for treating CNV, their effectiveness in destroying new blood vessels is limited, and invasive intravitreal administration is required. Additionally, other drugs that destroy established neovessels, such as combretastatin A‐4, may have systemic side effects that limit their therapeutic benefits. To overcome these shortcomings, a two‐pronged anti‐vascular approach is presented for CNV treatment using a photoactivatable nanoparticle system that can release a VEGF receptor inhibitor and a vascular disrupting agent when irradiated with 690 nm light. The nanoparticles can be injected intravenously to enable anti‐angiogenic and vascular disrupting combination therapy for CNV through light irradiation to the eyes. This approach can potentiate therapeutic effects while maintaining a favorable biosafety profile for choroidal vascular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Choroidal NeovascularizationAngiogenesis InhibitorsAnimalsDisease Models, AnimalMiceNanoparticlesHumansMice, Inbred C57BLVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

choroidal neovascularization (CNV)combretastatin A‐4cyanine prodrugnear‐infrared (NIR) light‐activationself‐assembled nanoparticles

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, 999077, China.
  • Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, 999077, China.
  • Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Hong Kong, 999077, China.
  • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, 510060, China.

ORCID-Profile: Weiping Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xu, S., Li, J., Long, K., Liang, X., & Wang, W. (2024). Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization. Advanced Science. https://doi.org/10.1002/advs.202404218

Vancouver

Xu S, Li J, Long K, Liang X, Wang W. Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization. Advanced Science. 2024. doi:10.1002/advs.202404218

BibTeX
@article{Xu2024,
  author = {Xu, Shuting and Li, Jia and Long, Kaiqi and Liang, Xiaoling and Wang, Weiping},
  title = {Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202404218}
}
Kostenlos starten →